Laboratory monitoring of COVID-19 patients and importance of coagulopathy markers [Лабораторный мониторинг COVID-19 и значение определения маркеров коагулопатии]

J. Khizroeva, A. Makatsariya, V. Bitsadze, M. Tretyakova, E. Slukhanchuk, I. Elalamy, J. Gris, L. Radetskaya, N. Makatsariya, Y. Sulina, V. Tsibizova, A. Shkoda, D. Blinov,

The pandemic of a novel coronavirus infection COVID-19 has become a real challenge to the mankind and medical community and has raised a number of medical and social issues. Based on the currently available information on COVID-19 clinical cases, it follows that COVID-19 patients in critical condition exhibit a clinical picture of disseminated intravascular coagulation (DIC), septic shock with developing multiple organ failure, which justifies use of anticoagulant therapy in COVID-19 patients. In addition to isolating virus RNA from biological material and polymerase chain reaction diagnostics, use of simple and easily accessible laboratory blood markers is necessary for management of COVID-19 patients. If the activation of coagulation processes is sufficient enough, consumption of platelets and blood clotting factors can be diagnosed by laboratory methods as prolongation of routine blood clotting tests and increasing thrombocytopenia. Hyperfibrinogenemia, increased D-dimer level, prolonged prothrombin time, thrombocytopenia, lymphopenia, leukocytopenia, increased concentration of interleukin-6 and ferritin are observed in most COVID-19 patients. The degree of increase in these changes correlates with severity of the inflammatory process and serves as a prognostically unfavorable sign. Here we discuss value of laboratory monitoring playing an essential role in such pathological crisis that contributes to patient screening, diagnosis as well as further monitoring, treatment and rehabilitation. © 2020 Universidad de Antioquia. All rights reserved.


Похожие публикации




  • 1. Version of Record от 2021-04-27


Об авторах
  • J. Khizroeva
    Sechenov University, 62 Str. Zemlyanoi Val, Moscow, 109004, Russian Federation
  • A. Makatsariya
    «Medical Center» LLC, 15/1 Timura Frunze Str., Moscow, 119021, Russian Federation
  • V. Bitsadze
    Petrovsky National Research Centre of Surgery, 2 Abrikosovsky Lane, Moscow, 119991, Russian Federation
  • M. Tretyakova
    Medicine Sorbonne University, 12 Rue de l'École de Médecine, Paris, 75006, France
  • E. Slukhanchuk
    Hospital Tenon, 4 Rue de la Chine, Paris, 75020, France
  • I. Elalamy
    University of Montpellier, Paris, France
  • J. Gris
    Almazov National Medical Research Centre, Health Ministry of Russian Federation, 2 Akkuratova Str., Saint Petersburg, 197341, Russian Federation
  • L. Radetskaya
    City Clinical Hospital № 67 named after L.A. Vorokhobov, Moscow Healthcare Department, 2/44 Salyama Adilya Str., Moscow, 123423, Russian Federation
  • N. Makatsariya
    Institute for Preventive and Social Medicine, 4-10 Sadovaya-Triumfalnaya Str., Moscow, 127006, Russian Federation
  • Y. Sulina
    Lapino Clinic Hospital, MD Medical Group, 1st Uspenskoye Highway, 111, Moscow Region, Odintsovo District, Lapino, 143081, Russian Federation
  • V. Tsibizova
    Moscow Haass Medical - Social Institute, 5, 1-1a 2nd Brestskaya Str., Moscow, 123056, Russian Federation
  • A. Shkoda
  • D. Blinov
Название журнала
  • Obstetrics, Gynecology and Reproduction
  • 14
  • 2
  • 132-147
Ключевые слова
  • D dimer; fibrinogen; phospholipid antibody; procalcitonin; activated partial thromboplastin time; Article; blood brain barrier; blood clotting disorder; coronavirus disease 2019; disease severity; enzyme linked immunosorbent assay; human; hyperferritinemia; laboratory diagnosis; leukopenia; lymphocytopenia; nonhuman; patient monitoring; polymerase chain reaction; pregnant woman; prothrombin time; screening; serology; thrombocytopenia
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC
Правовой статус документа
  • Свободная лицензия
  • scopus